Benjamin Leporq1, Sophie Gaillard1, Liadeh Cuminal2, Valerie Hervieu3, Olivier Guillaud4, Jerome Dumortier4, Pierre-Jean Valette5, and Olivier Beuf1
1CREATIS CNRS UMR 5220; Inserm U1206; INSA-Lyon; UCBL Lyon 1, Université de Lyon, Villeurbanne, France, 2Department of Radiology, CHU Edouard Herriot, Lyon, France, 3Department of Pathology, CHU Edouard Herriot, Lyon, France, 4Department of Hepato-Gastro-Enterology, CHU Edouard Herriot, Lyon, France, 5Department of Radiology, CHU Lyon Sud, Lyon, France
Synopsis
Whereas NASH is associated with poor long-term
outcome, widespread screening is not currently feasible given
that a definitive diagnosis of NASH can only be made through liver biopsy. In
this study, a virtual liver biopsy was developed with machine learning from
mixed multiparametric MRI radiomics and biological data.
Introduction
In the past decade, an epidemic increase in
non-alcoholic fatty liver disease (NAFLD) prevalence has been observed in
Western countries and NAFLD is among the most common causes of chronic liver
disease with a prevalence ranging between 17 and 46% (1). NAFLD include simple steatosis and
nonalcoholic steato-hepatitis (NASH). Whereas simple steatosis has good
prognosis, NASH is associated with poor long-term outcome (2) and is
characterized by steatosis, hepatocyte ballooning, inflammation, with or
without fibrosis at histology. About 20% of NASH patients develop cirrhosis or
hepatocellular carcinoma, so that NASH has become the fastest growing cause of
liver-related morbidity/mortality worldwide (3). Widespread
screening is not currently feasible given that a definitive diagnosis of NASH
can only be made through identification of the characteristic histopathologic
pattern on liver biopsy (4). Therefore, there
is a pressing unmet medical need for reliable and accurate non-invasive tools
to evaluate liver steatosis, fibrosis and inflammation simultaneously.
The aim of this study was to develop a virtual liver
biopsy based on multiparametric MRI (mpMRI) radiomics and biological data.Methods
70 patients with chronic liver diseases,
histology (ISHAK classification), blood serum markers and 3.0T mpMRI data
available were retrospectively enrolled from the HEPATOMAP database.
Gd-BOPTA-enhanced
(t = 20 min) fat-suppressed T1w images were used as a radiomic
fingerprint. PDFF-map was computed from chemical-shift-encoded acquisition
according to (5). ASAT, ALAT and Gamma GT-values were recorded.
From BOPTA-enhanced radiomic fingerprint, the liver were manually
segmented to extract the radiome including 87 features describing shape, size,
distribution and texture in images and frequency domain (Fig.1). Overall, 91
features were integrated. The learning base dimension was reduced using a
backward selection by thresholding on t-test p-value (t < 0.05). Two models
were established to predict advanced fibrosis (F > 2, n = 35) and
inflammation (A > 1, n = 46). To predict inflammation, a k-nearest neighbor algorithm with a
cosine node function and 10 neighbors was used as a classifier. To predict
fibrosis, a support vector machine with a linear kernel was used as a
classifier. Steatosis grades were predicted without classifier and directly
from the mean PDFF-value. Internal validation was performed with a holdout
cross-validation method (75% of data used for training and 25% for test).Results
Diagnosis performances to predict steatosis grades, advanced fibrosis and
inflammation are summarized in Fig.2.Discussion
This work shows the feasibility to predict key liver
histological characteristics (steatosis, fibrosis and inflammation) with mixed
radiomics and biological data in patients with chronic liver diseases.
Limitations of the study are the absence of external validation and the
heterogeneity of etiologies in the database. Shared multicenter data are
mandatory to extend this proof of concept to NASH only, to perform a thinner
classification, and to obtain an external validation.Acknowledgements
This work was performed within the framework of LABEX
PRIMES (ANR-11-LABX-0063), program "Investissements d'Avenir"
(ANR-11-IDEX-0007).
References
(1) Chalasani
N et al. Hepatology 2012; 55(6):2005-2023.
(2)
Angulo P et al.
Gastroenterology 2015; 149(2):389-397.
(3) Satapathy
SK et al. Semin Liver Dis 2015; 35(3):221-235
(4)
Chalasani N et al. Hepatology. 2018; 67:328–357
(5) Leporq
B et al. Eur Radiol 2013; 23(8):2175-2186